Spero Therapeutics (SPRO) EBIT Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 12.69% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 75.16% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -347.04% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 80.62% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 1.27% |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 8.65% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1,386.07% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 48.83% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.83% |
| Dec 31, 2025 | 223.68% |
| Sep 30, 2025 | 57.42% |
| Jun 30, 2025 | 87.18% |
| Mar 31, 2025 | -5.36% |
| Dec 31, 2024 | -146.63% |
| Sep 30, 2024 | -861.38% |
| Jun 30, 2024 | -47.87% |
| Mar 31, 2024 | 1.72% |
| Dec 31, 2023 | 103.41% |
| Sep 30, 2023 | 83.43% |
| Jun 30, 2023 | 50.58% |
| Mar 31, 2023 | 52.90% |
| Dec 31, 2022 | 197.34% |
| Sep 30, 2022 | 48.17% |
| Jun 30, 2022 | -40.65% |
| Mar 31, 2022 | -55.68% |
| Dec 31, 2021 | -46.32% |
| Sep 30, 2021 | -18.42% |
| Jun 30, 2021 | -0.36% |
| Mar 31, 2021 | 14.98% |
| Dec 31, 2020 | 27.38% |
| Sep 30, 2020 | -5.75% |
| Jun 30, 2020 | -35.34% |
| Mar 31, 2020 | -300.65% |
| Dec 31, 2019 | -133.52% |
| Sep 30, 2019 | -64.47% |
| Jun 30, 2019 | -36.92% |
| Mar 31, 2019 | 47.34% |
| Dec 31, 2018 | 20.83% |
| Sep 30, 2018 | -9.72% |
| Jun 30, 2018 | 1.91% |
| Mar 31, 2018 | -42.33% |
| Dec 31, 2017 | -58.91% |
| Sep 30, 2017 | -25.93% |